The Skin Cancer Drugs Market: 2025 - 2034 - Opportunities, Challenges, Strategies & Forecasts
Release Date: January 2025
Number of Pages: 214 Number of Tables and Figures: 48 Synopsis: Skin cancer remains one of the most prevalent malignancies worldwide, marked by the unchecked proliferation of abnormal skin cells. While most skin cancers, excluding melanoma, are generally non life-threatening, early detection and treatment remain crucial. Failing to treat skin cancer in its early stages can result in permanent functional and cosmetic damage as tumors spread, invading essential tissues and organs. Surgical intervention has traditionally been the cornerstone of skin cancer treatment. However, the landscape is rapidly evolving, as drug therapies, including chemotherapy, immunotherapy, and targeted treatments, are becoming increasingly vital in managing advanced cases. The focus of pharmaceutical innovation is particularly strong in the areas of melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). Significant investments are being poured into the pipeline, with an emphasis on developing novel agents that offer better efficacy and decrease side effects. As breakthrough therapies continue to reshape the treatment paradigm, the skin cancer drug market is set for significant growth. The market is expected to reach nearly $6 billion by the end of 2025 with a projected CAGR of 5.6% from 2025 to 2028, driven by a surge in both innovation and demand for more effective treatment options. |
The “Skin Cancer Drugs Market: 2025 – 2034 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the skin cancer drugs ecosystem including therapeutic areas, treatment options, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for skin cancer drugs from 2025 through to 2034. The forecasts are segmented for 3 drug classes, 4 therapeutic categories, 5 regions and 26 leading countries.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2025 clinical pipeline dataset.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and 2025 clinical pipeline dataset.
For a Sample and Table of Contents please contact [email protected]
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
Company Wide License (Global Site): USD 6,500
Key Findings:
The report has the following key findings:
Topics Covered:
The report covers the following topics:
Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
Key Questions Answered:
The report provides answers to the following key questions:
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
Pricing: The report is available for the following price:
Single User License: USD 2,500
Company Wide License (Single Site): USD 3,500
Company Wide License (Global Site): USD 6,500
Key Findings:
The report has the following key findings:
- Drug developers continue to invest heavily in novel drug development programs for skin cancer, particularly in the areas of melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). Collectively, these three indications now constitute over 80% of all drug development programs for skin cancers, indicating a strong focus on addressing the most prevalent forms of skin cancer.
- The skin cancer drugs market has shown resilience and is expected to reach the size of nearly $6 billion by the end of 2025 growing at a CAGR of approximately 5.6% from 2025 to 2028. This growth trajectory reflects the increasing incidence of skin cancer, ongoing advancements in treatment modalities, and a surge in drug approvals.
- Immunotherapies, particularly monoclonal antibodies, continue to solidify their role in the skin cancer drug market. Recent approvals include Cosibelimab (Unloxcyt) in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a PD-L1 blocking antibody that enhances immune response against cancer cells. Additionally, the FDA approved Opdivo Qvantig, a subcutaneous formulation of nivolumab, for melanoma and other solid tumors, offering a more convenient alternative to intravenous infusions. These developments highlight the growing impact of monoclonal antibodies in improving treatment outcomes and patient convenience.
- The focus on late-stage drug development programs remains robust, with a significant emphasis on monoclonal antibodies, IDO1 inhibitors, BRAF and MEK inhibitors, tyrosine kinase inhibitors (TKIs), and novel oncolytic viruses and vaccines. These therapies are designed to enhance efficacy and address resistance mechanisms observed in current treatments.
- An increasing number of companies are competing for a larger share of the skin cancer market by investing in pipeline candidates and combination therapies. Strategic mergers and acquisitions play a key role, such as Regeneron Pharmaceuticals' $250 million acquisition of Checkmate Pharmaceuticals in April 2022. This deal brought vidutolimod, an investigational immunotherapy designed to activate the immune system against skin cancers, into Regeneron’s portfolio.
Topics Covered:
The report covers the following topics:
- Skin cancer drugs ecosystem
- Market drivers and barriers
- Review of melanoma and non-melanoma skin cancers
- Role of drugs in skin cancer and key trends
- Analysis of key drug classes and 40 plus leading skin cancer drugs
- Future drug development pipeline with almost 100 candidates
- Industry roadmap and value chain
- Profiles and strategies of 79 leading ecosystem players, including skin cancer drug developers
- Strategic recommendations for ecosystem players
- Market analysis and forecasts from 2025 till 2034
Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
- Drug Class
- Chemotherapy
- Immunotherapy
- Targeted Agents & Other Drugs
- Therapeutic Category
- Melanoma
- BCC/SCC (Basal and Squamous Cell Carcinoma)
- MCC (Merkel Cell Carcinoma)
- Other Skin Cancers
- Regional Markets
- Asia Pacific
- Europe
- Middle East & Africa
- North America
- Latin & Central America
- Country Markets
- Australia
- Brazil
- Canada
- China
- Egypt
- France
- Germany
- Greece
- India
- Israel
- Italy
- Japan
- Mexico
- Netherlands
- Poland
- Portugal
- Russia
- Saudi Arabia
- South Africa
- South Korea
- Spain
- Switzerland
- Taiwan
- Turkey
- UK
- USA
Key Questions Answered:
The report provides answers to the following key questions:
- How big is the skin cancer drugs opportunity?
- What trends, challenges and barriers are influencing its growth?
- How is the ecosystem evolving by segment and region?
- What will the market size be in 2034 and at what rate will it grow?
- Which countries and submarkets will see the highest percentage of growth?
- What does the drug development pipeline look like in 2025 for skin cancer?
- What are the prospects of immunotherapy drugs in skin cancer treatment?
- How big is the market for melanoma drugs?
- Who are the key market players and what are their strategies?
- How will patent expirations of innovator drugs impact the market?
- What strategies should skin cancer drug developers adopt to remain competitive?
List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:
AB Science
AbbVie Adaptimmune Therapeutics Adgero Biopharmaceuticals Agenus Allergen Almirall Altor BioScience Amgen Angimmune Antigen Express APCure Apexigen Array Biopharma Ascend Biopharmaceuticals Astellas Pharma AstraZeneca Athenex Autotelic Basilea Pharmaceutica Bausch Health Bayer Berg Pharma Biodesix Biogen BioLineRx Bioniz BioNTech Biosceptre Biothera Pharmaceuticals Boehringer Ingelheim Boston Biomedical Brickell Biotech BrightPath Biotherapeutics Bristol-Myers Squibb (BMS) Celgene Celldex Therapeutics Celltrion CEL-SCI Corporation Centre for Genomic Regulation Checkmate Pharmaceuticals Chugai Pharmaceutical Company Cipla Circio Cutanea Life Sciences Cytori Therapeutics CytRx Corporation Daiichi Sankyo DermBiont DFB Soria Dr. Reddy’s Laboratories Dynavax Technologies Eisai Elevar Therapeutics Elios Therapeutics Equillium |
Eterna Therapeutics
Exelixis FDA Fresenius Kabi G&E Herbal Biotechnology Galderma Galectin Therapeutics Genentech Generex Biotechnology Corporation Genzyme Corporation Glycotope GSK (GlaxoSmithKline) HedgePath Pharmaceuticals HiberCell Hikma Pharmaceuticals Huya Bioscience Idera Pharmaceuticals Ignyta Immune Design ImmunityBio Inc. Immunocore Incyte Corporation Infinity Pharmaceuticals Inhibitor Therapeutics Innate Pharma Innovent Biologics Inovio Inovio Pharmaceutical Iovance Biotherapeutics Ipsen IRX Therapeutics Jiangsu Hengrui Medicine Co Johnson & Johnson Karyopharm Therapeutics Kintara Therapeutics Kowa Krystal Biotech LadRx Corporation Leap Therapeutics LEO Pharma Lilly LSK BioPharma Lumos Pharma Lupin MacroGenics Mayne Pharma Group MD Anderson Cancer Center MedImmune Medivir Merck & Co Merck KGaA Millennium Pharmaceuticals miRagen Therapeutics Mirati Therapeutics Moderna Molecular Templates Morphotek |
Mylan
NanoCarrier Nanology NantCell NantKwest Nektar Therapeutics Neon Therapeutics Nestlé Neumedicines NewLink Genetics Novartis Oncolys Biopharma Oncolytics Biotech OncoSec Medical Oncotelic Ono Pharmaceutical Otsuka Holdings Company Parker Institute for Cancer Immunotherapy PellePharm Pfizer Philogen Phio Pharmaceuticals Photogen Technologies Inc Pierre Fabre Plexxikon Polaris Pharmaceuticals Poli Group Polynoma Privo Technologies Prometheus Laboratories Provectus Biopharmaceuticals Pyxis Oncology Reata Pharmaceuticals Regeneron Pharmaceutical Rhizen Pharmaceuticals Roche Sanofi Sesen Bio Sol-Gel Technologies Soligenix Sumitomo Dainippon Pharma Summit Therapeutics Sun Pharma Syndax Pharmaceuticals Taiho Pharmaceutical Company Takara Bio Takeda Targovax Teva Pharmaceutical Industries Transgene Trillium Therapeutics TriSalus Life Sciences Ultimovacs Vidac Pharma Viralytics X4 Pharmaceuticals |
Our Research & Services |
Company |
MoreSubscribe for Latest Updates
Privacy Policy Disclosures Contact Us: [email protected] © 2025 SNS Research |